CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference10 articles.
1. A decade of immune-checkpoint inhibitors in cancer therapy;Robert;Nat Commun,2020
2. Pembrolizumab versus chemotherapy for PDL1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016
3. Atezolizumab for first-line treatment of PD-L1 selected patients with NSCLC;Herbst;N Engl J Med,2020
4. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data;Passaro;Cancer Treat Rev,2020
5. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer;Peters;Ann Oncol,2019
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy;Biomedicines;2024-03-19
2. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases;Lung Cancer;2023-10
3. Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer;Frontiers in Immunology;2023-07-03
4. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer;Cellular Oncology;2023-05-23
5. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers;Current Oncology;2023-02-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3